|
Jacqueline Barry PhD
Chief Clinical Officer
Cell and Gene Therapy Catapult
London
|
"Jacqueline Barry is a senior business leader with over 20 years of experience in biologics and advanced therapies. Her career has focused on supporting the translation of research from the laboratory bench through to gaining regulatory approval and then clinical delivery. She possesses a blend of expertise across the areas of regulation, quality, Good Manufacturing Practice, science, strategy, commercial development and management.
Jacqueline holds an executive position at the Cell and Gene Therapy Catapult, where she leads a specialist team that is dedicated to developing regulatory and translational strategies for advanced therapy products, as well as working to ensure that the wider ecosystem supports the development and adoption of these therapies in the UK and beyond. She also leads a network of advanced therapy treatment centres in the UK that aim to accelerate patient access to these transformative therapies.
Jacqueline sits on a number of advisory boards and is on the board of directors at the International Society for Stem Cell Research (ISSCR).
She feels passionately about making advanced therapies more widely available for patients and over her career she has worked closely with industry partners and policy makers to support the adoption of these therapies by healthcare systems."
Jacqueline holds an executive position at the Cell and Gene Therapy Catapult, where she leads a specialist team that is dedicated to developing regulatory and translational strategies for advanced therapy products, as well as working to ensure that the wider ecosystem supports the development and adoption of these therapies in the UK and beyond. She also leads a network of advanced therapy treatment centres in the UK that aim to accelerate patient access to these transformative therapies.
Jacqueline sits on a number of advisory boards and is on the board of directors at the International Society for Stem Cell Research (ISSCR).
She feels passionately about making advanced therapies more widely available for patients and over her career she has worked closely with industry partners and policy makers to support the adoption of these therapies by healthcare systems."